

Call for Papers

The Journal of Blood and Biotherapy invites original submissions of high-quality, innovative research to be considered for publication in its upcoming issues. As an international, peer-reviewed journal dedicated to advancing science and innovation in hematology, transfusion medicine, and biotherapy, we seek work that pushes the boundaries of knowledge, fosters interdisciplinary collaboration, and drives translational impact to improve patient care worldwide.

Our journal serves as a premier platform for researchers, clinicians, and industry partners globally to share breakthroughs, exchange insights, and address critical challenges in blood disorders, cellular therapies, and biological treatments. We prioritize translational research that bridges the gap between scientific discovery and clinical application, ensuring that cutting-edge findings translate into tangible improvements in patient outcomes.

About the Journal

The Journal of Blood and Biotherapy publishes four issues per year, welcoming submissions from researchers across the globe. We accept a diverse range of content types, including original research articles, comprehensive reviews, case reports, short communications, and letters to the editor—all focused on advancing the fields of blood and biotherapy.

Keywords: Hematology, Transfusion Medicine, Blood, Biotherapy

Scope of Submissions

We invite submissions covering a broad spectrum of topics at the interface of blood science and biotherapy. Contributions may address, but are not limited to, the following areas, which have been organized to ensure logical coherence and minimize overlap.

➤ Hematology and Blood Disorders

- Pathophysiology, diagnosis, and therapeutic strategies for anemia, hemoglobinopathies, coagulation disorders, and hematologic malignancies such as leukemias, lymphomas, and myeloma.
- Recent advances in hematopoietic stem cell transplantation and regenerative medicine for hematologic conditions.

➤ Transfusion Medicine and Immunohematology

- Blood product safety, innovations in storage and preservation, and personalized transfusion strategies.
- Management of transfusion-related adverse events and prevention of alloimmunization.
- Blood group antigens and antibodies: their roles in transfusion compatibility and hemolytic disease, together with blood group genetics and molecular biology.

➤ Cellular and Immune Therapies

- Development and clinical application of CAR-T cells, gene therapies, and engineered immune cell products.

This open access article is distributed in accordance with the terms of the [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/) License. Users may freely use, share, modify, and republish the content commercially or non-commercially, as long as accurate original citation is retained.

© 2026 The Author(s). *Journal of Blood and Biotherapy* published by IAABG, the International Association of Asia-Pacific Blood Types and Genomics.

- Translational use of CRISPR-based technologies, RNA therapeutics, and viral vectors in hematologic diseases.
- Immune checkpoint inhibitors, monoclonal antibodies, and therapeutic vaccines targeting hematologic malignancies.
- Mechanisms of immune tolerance and rejection in hematopoietic stem cell transplantation.

➤Biopharmaceuticals and Regulatory Science

- Preclinical and clinical development of biologic agents, including recombinant proteins, biosimilars, and novel biologics.
- Regulatory frameworks, ethical considerations, and commercialization pathways for hematology-focused biopharmaceuticals.

➤Emerging Technologies

- AI-driven diagnostic tools, biomarker discovery platforms, and clinical applications of liquid biopsy in blood diseases.
- Microfluidic devices and nanotechnology-enabled tools for real-time monitoring and management of hematologic disorders.

Submission Guidelines

- All submissions must be original work, not previously published, and not under consideration for publication elsewhere. Manuscripts that have been presented at conferences may be submitted, provided they have not been formally published in conference proceedings.
- Manuscripts should be written in clear, concise English, adhering to the journal's style guidelines (available on our official website).
- Authors must ensure that all research complies with ethical standards, including informed consent for human subjects and proper animal care protocols (where applicable). Documentation of ethical approval should be included in the manuscript.
- All submissions will undergo a rigorous double-blind peer review process to ensure scientific rigor, originality, and relevance to the journal's scope.
- Authors are required to submit a cover letter, a completed manuscript (including abstract, keywords, introduction, methods, results, discussion, conclusion, and references), and any supplementary materials (e.g., figures, tables, supplementary data).
- All articles published in JOFBBT carry a CrossRef DOI and are published Open Access. This ensures permanent availability and widest possible dissemination, thereby enhancing their global recognition and citation impact.

Important Dates

- Submission Deadline: Early submission is encouraged.
- Peer Review Period: 4–6 weeks from submission
- Expected Publication Date: Submissions are accepted on a rolling basis.

How to Submit

Manuscripts should be submitted exclusively through the journal's online submission portal: Online Submission Portal Link. For questions regarding submissions, please contact the Editorial Office at the Editorial Office Email Address: office@jofbbt.com.

Contact Information

Editorial Office: Room No. 532B on 5/F Star House, No. 3 Salisbury Road, Tsim Sha Tsui, Kowloon, Hong Kong

Email: office@jofbbt.com

Official Website: Journal of Blood and Biotherapy <https://www.jofbbt.com/>

We look forward to receiving your groundbreaking submissions and continuing to advance the science of blood and biotherapy together.

Editorial Board

Journal of Blood and Biotherapy